Evidence map›Paper›PMID 33061801›Full record

ArticleInternational journal of biological sciences2020

miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway.

Chao Hu, Mengxia Yu, Chenying Li, Yungui Wang, Xia Li, Bryan Ulrich, Rui Su, Lei Dong, Hengyou Weng, Huilin Huang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. mFrontiers in cell and developmental biology · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. The Role of NCancers · 2022
    Review
  8. Review
  9. NCancer communications (London, England) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Chao HuDepartment of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, P.R. China.
Mengxia YuDepartment of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, 216 Huansha Road, Hangzhou, 310006, P.R. China.
Chenying LiDepartment of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, P.R. China.
Yungui WangDepartment of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, P.R. China.
Xia LiDepartment of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, P.R. China.
Bryan UlrichSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA.
Rui SuDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Lei DongDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Hengyou WengDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Huilin HuangDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Xi JiangDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Jianjun ChenDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Jie JinDepartment of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, P.R. China.
University of Cincinnati · USUniversity of Chicago · US

Funding

Targeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8M
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3M
Targeting TET1 signaling to treat acute myeloid leukemiaR01CA211614 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.3M
The function and underlying mechanism of TET1 in myelodysplastic syndromesR01DK124116 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2023
$2.2M
The role and mechanism of FTO in leukemogenesis and drug responseR01CA214965 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.1M
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemiaR01CA182528 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7M
NCI NIH HHS R01 CA182528NCI NIH HHS R01 CA211614NCI NIH HHS R01 CA214965NCI NIH HHS R01 CA236399NCI NIH HHS R01 CA243386NIDDK NIH HHS R01 DK124116
6 · The paper itself

Abstract

MicroRNAs (miRNAs) and N

Indexed as

Leukemia, Myeloid, AcuteMicroRNAsCell Line, TumorCell ProliferationGenes, Tumor SuppressorHippo Signaling PathwayHumansMicroRNAsMIRN550 microRNA, humanacute myeloid leukemiaapoptosismiR-550-1proliferationWWTR1

Identifiers

PMID33061801
PMCPMC7545716
OpenAlexW3085954937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.